Haisco Pharmaceutical released its 2026 interim report. Total operating revenue was 3.096 billion yuan, net profit attributable to the parent company was 851 million yuan, and net operating cash inflow was 761 million yuan. The company's latest asset-liability ratio was 38.89%, up 2.11 percentage points from the previous quarter; gross margin was 80.24%, down 1.15 percentage points from the previous quarter; ROE was 17.68%. Diluted earnings per share was 0.76 yuan, total asset turnover was 0.42 times, and inventory turnover was 1.86 times, down 1.82% year on year. The number of shareholders was 24,500, and the top ten shareholders held 82.66% of total share capital.
Xizang Haisco Pharmaceutical Group Co LtdInterim report shows strong net profit of 851 million yuan on 3.096 billion revenue.
